Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0119 • ACR Convergence 2022
Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions Varies by Geographic Location of Residence
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Steven Katz², Eileen Davidson³, Clare Hildebrandt⁴, Katie Lin¹, Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: Rheumatology services in Canada are largely restricted to urban centres, resulting in significant access difficulties for residents of rural and remote locations. As a…
Abstract Number: 0242 • ACR Convergence 2022
Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging
Lukas Folle¹, Sara Bayat², Arnd Kleyer³, Filippo Fagni², Lorenz Kapsner⁴, Maja Schlereth⁵, Timo Meinderink², Katharina Breininger⁵, Koray Tascilar³, Gerhard Kroenke³, Michael Uder⁶, MIchael Sticherling⁷, Sebastian Bickelhaupt⁴, Georg Schett⁸, Andreas Maier⁹, Frank Roemer¹⁰ and David Simon³, ¹Friedrich-Alexander-Universitaet Erlangen Nürnberg, Erlangen, Germany, ²University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴University Hospital Erlangen; Institute of Radiology, Erlangen, Germany, ⁵Friedrich-Alexander Universität Erlangen-Nürnberg, Artificial Intelligence in Medical Imaging, Erlangen, Germany, ⁶University Hospital Erlangen; Lehrstuhl für Diagnostische Radiologie, Erlangen, Germany, ⁷University Hospital Erlangen; Institute of Dermatology, Erlangen, Germany, ⁸Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Friedrich-Alexander-Universität Erlangen-Nürnberg, Lehrstuhl für Mustererkennung, Erlangen, Germany, ¹⁰Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany
Background/Purpose: To evaluate (i) whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using MRI data based on…
Abstract Number: 0258 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents
Sascha Heckert¹, Tjardo Maarseveen², Emiel Marges², Arvind Chopra³, David Vega Morales⁴, Riette Du Toit⁵, Annette van der Helm-van Mil⁶, Tom Huizinga², CF Allaart² and Sytske Anne Bergstra⁷, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Center for Rheumatic Diseases, Pune, Maharashtra, India, ⁴Hospital General de Zona 17, Instituto Mexicano del Seguro Social, Monterrey, Mexico, ⁵Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa, ⁶Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, ⁷LUMC, Leiden, Netherlands
Background/Purpose: Interstitial lung disease (ILD) is a spectrum of inflammatory and fibrotic lung diseases, and can be associated with RA (RA-ILD). The reported prevalence in…
Abstract Number: 0275 • ACR Convergence 2022
Exploratory Analysis of Filgotinib Safety Data in Patients with Moderately to Severely Active RA and an Increased Risk of Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials
Maya Buch¹, Gerd Burmester², Xavier Mariette³, Christina Charles-Schoeman⁴, Vijay Rajendran⁵, Pieter-Jan Stiers⁶, Agustin Cerani⁶, Paul Van Hoek⁶, Katrien Van Beneden⁶, Yoshiya Tanaka⁷, Hendrik Schulze-Koops⁸, Rene Westhovens⁹ and Ennio Giulio Favalli¹⁰, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Charité University Medicine Berlin, Berlin, Germany, ³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁴Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ⁵Galapagos NV, Gent, Belgium, ⁶Galapagos NV, Mechelen, Belgium, ⁷University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁸Ludwig-Maximilians-University Munich, Munich, Germany, ⁹University Hospitals Leuven, Leuven, Belgium, ¹⁰University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy
Background/Purpose: The safety profile of filgotinib (FIL), a second-generation oral Janus kinase (JAK) 1 preferential inhibitor approved in Europe, Japan, and the UK for treatment…
Abstract Number: 0292 • ACR Convergence 2022
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Andrea Rubbert-Roth¹, Adriana Kakehasi², Tsutomu Takeuchi³, Marc Schmalzing⁴, Hannah Palac⁵, Jianzhong Liu⁵, Samuel Anyanwu⁵, Ralph Lippe⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³Keio University and Saitama Medical University, Tokyo, Japan, ⁴University Hospital Wuerzburg, Wuerzburg, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc, Wiesbaden, Germany, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…
Abstract Number: 0311 • ACR Convergence 2022
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zunsemetinib, an Investigational Oral MK2 Inhibitor, at 80 Mg and 120 Mg Twice Daily Dose Levels in Healthy Subjects
Ajay Aggarwal¹, David Burt², Laura Connelly², Joseph Monahan² and Jessea Lu², ¹Aclaris Therapeutics, Wellesley, MA, ²Aclaris Therapeutics, Inc., Wayne, PA
Background/Purpose: Zunsemetinib is an orally available potent and selective small molecule inhibitor of the p38α MAPK/MK2 signaling axis. Aclaris Therapeutics, Inc. is developing zunsemetinib for…
Abstract Number: 0533 • ACR Convergence 2022
Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity
Timothy Wilson¹, Jacob Welch², Marie Feser², Elizabeth Bemis², Claudia Lugo², Gary S. Firestein³, Thomas F. Bumol⁴, Jill Norris⁵, V. Michael Holers⁶, Kevin D Deane⁷ and Kristen Demoruelle², ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of California, San Diego, San Diego, CA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Aurora, CO, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO
Background/Purpose: Presence of systemic anti-CCP-IgG antibodies in individuals without inflammatory arthritis (IA) strongly predicts developing future classified RA. However, published data also demonstrate that 50-70%…
Abstract Number: 0591 • ACR Convergence 2022
Deficiency of FUN14 Domain-Containing Protein 1-Mediated Mitophagy in Fibroblast-like Synoviocytes Causes Aggressive Behaviors Leading to Joint Destruction in Rheumatoid Arthritis
Qian Zhang¹, Tao Wu¹, Jian-da Ma², Yao-Wei Zou¹, Xue-Pei Zhang¹, Hu-Wei Zheng¹, Jun Jing¹, Yao-yao Zou³, Le-feng Chen¹ and Lie Dai², ¹Sun Yat-Sen University, Guangzhou, China, ²Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ³Guangdong People's Hospital, Guangzhou, China
Background/Purpose: Synovial fibroblast-like synoviocytes (FLSs) actively participate in the pathogenesis of rheumatoid arthritis (RA). FUN14 domain-containing protein 1 (FUNDC1), a novel mitophagy receptor, plays critical…
Abstract Number: 0607 • ACR Convergence 2022
Cadherin 6 Regulates Rheumatoid Arthritis Fibroblasts-Like Synoviocyte Aggressiveness
Camilla Machado¹, Hyeonjeong Lee², Sho Sendo³, Narayanan Perumal⁴, Wei Wang⁵, David Boyle⁵ and Gary S. Firestein⁶, ¹UCSD, San Diego, CA, ²University of California San Diego, San Diego, CA, ³University California, San Diego (UCSD), La Jolla, CA, ⁴Eli Lilly Company, San Diego, ⁵University of California San Diego, San Diego, ⁶University of California, San Diego, San Diego, CA
Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) display an aggressive behavior. Previous studies have implicated cadherins in FLS function in this phenotype, which are type…
Abstract Number: 0625 • ACR Convergence 2022
Distinct Effects of JAK Inhibitor and TNF Inhibitors on Circulating B Cell Phenotypes in Rheumatoid Arthritis Patients
Mehreen Elahee¹, Kathryne Marks¹, Ifeoluwakiisi Adejoorin¹, Lin Chen¹, Derrick Todd¹, Jonathan Coblyn¹, Elena Massarotti¹, Susan Ritter¹, Daniel Solomon¹, Michael Weinblatt² and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Multiple DMARDs are used to treat rheumatoid arthritis (RA) yet, there are currently few tools to assess if DMARD treatment influences pathologic immune cell…
Abstract Number: 0757 • ACR Convergence 2022
Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
Pankti Reid¹, Sabina Sandigursky², Maria A. Lopez-Olivo³, Juhee Song⁴, Houssein Safa⁵, Samuel Cytryn⁶, Maryam Buni⁷, Anna Pavlick⁸, Michelle Krogsgaard, PhD⁹, Osama Abu-Shawer¹⁰, Mehmet Altan¹¹, Jeffrey Weber¹², Maria Suarez-Almazor¹³, Adi Diab¹⁴ and Noha Abdel-Wahab¹⁴, ¹University of Chicago Medical Center, Chicago, IL, ²NYU Langone Health, New York, NY, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁶Memorial Sloan Kettering Cancer Center, New York, NY, ⁷MD Anderson Cancer Center, Bellaire, TX, ⁸Medical Oncology, Weill Cornell Medical Center, New York, NY, ⁹Perlmutter Cancer Center, Department of Pathology, NYU Langone Health, New York, NY, ¹⁰Cleveland Clinic Foundation, Cleveland, OH, ¹¹Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ¹²NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, NY, ¹³MD Anderson Cancer Center, Houston, TX, ¹⁴UT MD Anderson Cancer Center, Houston, TX
Background/Purpose: Treatment with a combination of immune checkpoint inhibitors (ICI) has promising outcomes in many tumor types but carries higher adverse event risk than ICI…
Abstract Number: 0819 • ACR Convergence 2022
Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center
Anchal Sabharwal¹, Yuanqing Liu¹, Yazmin Rustomji¹ and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Connective tissue diseases (CTDs) are a category of autoimmune disease in which interstitial lung disease (ILD) is a common pulmonary manifestation. Due to the…
Abstract Number: 0897 • ACR Convergence 2022
Reasons for Multiple Biologic DMARD Switching and Characteristics of “Extreme Treatment Nonresponders” in Rheumatoid Arthritis
Gregory McDermott¹, Kumar Dahal¹, Su-Jin Moon², Thany Seyok¹, Dana Weisenfeld¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Despite the efficacy of modern biologic and small molecule medications, a significant proportion of RA patients have inadequate response to multiple therapies. These patients…
Abstract Number: 0913 • ACR Convergence 2022
Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis
Karam Jabri¹, Linda Burns² and Joseph Grisanti³, ¹University at Buffalo/Catholic Health, Depew, NY, ²Buffalo Rheumatology, Lancaster, NY, ³Buffalo Rheumatology & Medicine, Orchard Park, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of infection compared to healthy subjects (1). This is because of a multifactorial complex…
Abstract Number: 0929 • ACR Convergence 2022
Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases
Cara Kumar¹, Kristine Herrmann¹ and Martin Aringer², ¹Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany
Background/Purpose: While mostly remarkably safe, low dose methotrexate (MTX) occasionally causes life-threatening events. We analyzed all patients with rheumatic diseases and severe MTX toxicity between…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.